Skip to main content

Table 5 Proportion of patients who received more than 80% of the target dose

From: Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

  Number of patients (%)
Time from randomization DD/DI arm (N = 86) HDI arm(N = 80)
Induction 56 (65) 52 (65)
3 months 35 (49) 42 (64)
5 months 25 (42) 33 (55)
7 months 20 (36) 23 (43)